Avicanna September Recap

A Monthly Overview of Avicanna’s Announcements

As we said goodbye to a choppy August in the public markets, the September effect of a historically weak stock market returns had seen its fair share of downturns in the cannabis space. Never discouraged, we continued to focus on the execution of our R&D and commercialization strategies to drive long-term shareholder value. The following is the last month in review, filled with exciting news and milestones.

September 13, 2019

Avicanna Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders
  • Exclusive research agreement with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, Ontario Veterinary College, Department of Biomedical Sciences, as principal investigator.
  • Advances the research and development, and pre-clinical analysis of Avicanna’s proprietary prescription and over-the-counter (“OTC“) cannabinoid products and formulations
  • Focuses on evaluating a variety of dosage forms on pre-clinical models of several human psychiatric conditions, including depression, anxiety, schizophrenia, PTSD and substance abuse.
  • By using electrophysiology and behavioral methods with various Avicanna formulations and common to rare cannabinoids, this research is looking to uniquely determine brain cannabinoid levels and cerebral activity function.

September 30, 2019

Avicanna to Open its Next Phase Extraction Facility in Colombia’s Free Trade Zone
  • Avicanna plans to build a new industrial scale 11,000 sq. ft (>1,000 square meter) cannabinoid extraction and final product manufacturing facility in a Colombian free trade zone near Santa Marta, which is expected to provide for significant tax advantages.
  • New facility represents the third phase of the Company’s extraction strategy, building on its existing subsidiaries’ extraction and manufacturing operations in Colombia with current aggregate annual capacity of dried flower – post extraction and isolation – of approximately 100,000 kilograms.
  • The Company expects operations at the facility to commence in the second half of 2020.
  • Contributes to Avicanna’s expanding vertical integration strategy, including the use of cannabis sourced from Avicanna’s other majority owned Colombian based subsidiaries, Sativa Nativa S.A.S (“Sativa Nativa“) and Santa Marta Golden Hemp S.A.S. (“SMGH“), which are situated in Santa Marta.

October 2, 2019

Avicanna (TSX: AVCN) Announces First Commercial Sale of the Pura Earth Derma-Cosmetics line of CBD Products
  • Pura Earth™ is Avicanna’s derma-cosmetic line which utilizes a combination of purified cannabidiol (“CBD”) and other synergistic botanical ingredients designed to naturally regulate and nourish the skin.
  • The sale was completed through Avicanna’s wholly owned subsidiary, Avicanna LATAM S.A.S., to Percos S.A. (“Percos”), Avicanna’s exclusive distributor of Pura Earth™ derma-cosmetics products in Colombia.
  • The initial order from Percos included Avicanna’s Anti-Aging Treatment, Anti-Aging Serum, Clear Skin Treatment and Intensive Skin Conditioning Treatment.
  • The products are expected to be available for purchase in approximately 59 retail locations throughout Colombia later this month.
  • Avicanna expects to launch the Pura Earth™ brand in additional international jurisdictions in early 2020.
  • Pura Earth™ is produced with proprietary formulations using CBD isolate extracted by the Company’s majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH”), from cannabis grown and cultivated by SMGH.


September 10-12, 2019

International Cannabinoid Derived Pharmaceuticals Summit
  • Dr. Justin Grant, EVP Scientific Affairs participated on a panel entitled “An Overview and Considerations for Cannabinoid Formulation Development and Preclinical Research.” where he discussed:
    • Design considerations of various cannabis dosage forms.
    • Physicochemical limitations of cannabinoids and drug-excipient interactions.
    • Pre-clinical research studies to support product development and clinical trial applications.


September 23, 2019

12th Annual International Natural & Organic Cosmetics Conference
  • Avicanna was the only cannabinoid related company with the opportunity to present due to Avicanna’s biopharmaceutical and evidence-based focus.
  • CEO and Co-Founder Aras Azadian was a highlighted speaker on the global organic cosmetics industry and the use of CBD in cosmetic products and specifically Avicanna’s organic CBD cosmetic line Pura Earth at a leading industry conference in Berlin, Germany.

September 28-29, 2019

12th Annual International Natural & Organic Cosmetics Conference
  • Led by Adelaide Capital and Grit Capital the 47-person investor tour was intended to show the investment community our progress and highlights our infrastructure and competitive advantages.
  • The site visit to Avicanna’s cultivation subsidiaries, outlining the different phases of cultivation, extraction laboratories and duty-free zone, while highlighting the microclimate in which we cultivate and the positive result on plant health as a result of our strategic location.

September 4-6, 2019

September 30 – October 1, 2019

MJBizCon Int’l Toronto
MJBizDaily’s First Cannabis Latin American Cannabis Symposium, Bogotá
  • Aras Azadian, CEO participated on a panel discussing niche market opportunities and attracting international investors.


480 University Ave, Suite 1502
Toronto, ON M5G 1V2

Want to stay up to date? Subscribe to receive email updates.

© 2017-2019 Avicanna Inc. All Rights Reserved.

Sign up and join our Newsletter  

Stay updated with all latest
updates and news.